1. HIV In Mothers and Children

2. 2 What Is HIV/AIDS? Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). HIV attacks and destroys white blood cells, causing a defect in the body’s immune system.

3. 3 What Is HIV/AIDS? The immune system of an HIV-infected person becomes so weakened that it cannot protect itself from serious infections. When this happens, the person clinically has AIDS. AIDS may manifest as early as 2 years or as late as 10 years after infection with HIV.

4. 4 Number of People with HIV/AIDS by Region North America 890,000 Caribbean 330,000 Latin America 1.4 million Western Europe 500,000 Sub-Saharan Africa 22.5 million Eastern Europe & Central Asia 270,000 East Asia & Pacific 560,000 South and South East Asia 6.7 million Australia and New Zealand 12,000 North Africa & Middle East 210,000 Source: UNAIDS/WHO 1998.

5. 5 HIV Transmission Through Sexual Contact Of every 100 HIV infected adults, 75-85 have been infected through unprotected intercourse –70% of these infections are from heterosexual intercourse STDs increaseSTDs, especially ulcerative lesions in genitalia, increase risk of transmission Source: UNAIDS/WHO 1996.

6. 6 Modes of HIV Transmission Sexual intercourse Accidental exposure to blood/blood products (e.g., blood transfusions, shared needles, contaminated instruments) Mother to child during: –pregnancy –birth –breastfeeding

7. 7 Women and HIV Social Risk Factors –Illiteracy –Lack of awareness of preventive measures Biological risk factors –Twice as easy for women to contract HIV from men –Physiology of women (e.g., menstruation, intercourse) –Pregnancy-associated conditions (e.g., anemia, menorrhagia and hemorrhage) increase the need for blood transfusion

8. 8 HIV and Contraception Contraception with protection –Male condom (latex and vinyl) –Female condom –Nonoxynol-9 (antiviral spermicidal cream) 1 –Diaphragm 1 Methods appropriate for use by women with HIV. They should use a condom for their partner’s protection. –Hormonals (COCs, Implants, PICs) –Voluntary sterilization 1 Partial protection if used without condom

9. 9 Effect of AIDS on Pregnancy Infertility Repeated abortions Prematurity Intrauterine growth retardation Stillbirths Congenital abnormalities Embryopathies

10. 10 HIV Transmission from Mother to Infant AntenatalAntenatal –In utero by transplacental passage IntranatalIntranatal –Exposure to maternal blood and vaginal secretions during labor and delivery PostnatalPostnatal –Postpartum through breastfeeding Source: UNAIDS/WHO 1996; UNAIDS/WHO 1998.

11. 11 HIV Transmission from Mother to Infant 25-35% of all infants born to HIV-infected women in developing countries become infected 90% of HIV-infected infants and children were infected by mother Source: UNAIDS/WHO 1996; UNAIDS/WHO 1998.

12. approximately 600,000 HIV-infected infants are born every year–at least 1,600 every day–in resource-constrained countries. Transmission occurs during pregnancy, labor and delivery, and breastfeeding. The rate of mother to child transmission has been reduced to less than 5 percent among the limited number of HIV-infected women in developed countries.

13. high rates are largely due to the lack of access to: –HIV voluntary counseling and testing – replacement feeding –selective caesarean section –antiretroviral drug therapy

14. 14 HIV Transmission cannot HIV cannot be transmitted by: –Casual person to person contact at home or work or in social or public places –Food, air, water –Insect/mosquito bites –Coughing, sneezing, spitting –Shaking hands, touching, dry kissing or hugging –Swimming pools, toilets, etc.

15. 15 AIDS and Infants Symptoms generally develop by 6 months of age –Diarrhea –Failure to thrive Most of these children die before their second birthday Children born to HIV-infected parents are likely to become orphans

16. Reducing pediatric HIV infection and disease involves three stages: preventing HIV infection among women of childbearing age preventing unwanted pregnancy among HIV-positive women preventing mother to child transmission during pregnancy, labor and delivery, and breastfeeding

17. BENEFITS TO HIV TESTING EARLY COUNSELING AND TREATMENT OF HIV INFECTION ABILITY TO MAKE DECISIONS REGARDING PREGNANCY IMPLEMENTATION OF STRATEGIES TO ATTEMPT TO PREVENT TRANSMISSION TO FETUS

18. WHO SHOULD WE SCREEN? ALL PREGNANT WOMEN TARGETED TESTING FAILS TO IDENTIFY A SUBSTANTIAL PROPORTION OF HIV POSITIVE WOMEN

19. by two-thirdszidovudine (AZT) administered to the mother from 14 weeks of gestation and to the child during the first seven days after birth, reduced the risk of mother to child transmission among non- breastfeeding mothers by two-thirds. 37 percent reductionTwo similar studies conducted in Côte d’Ivoire and Burkina Faso among breastfeeding mothers demonstrated a 37 percent reduction in mother to child transmission. Anti-Retroviral Based Prevention Strategies

20. 47 percent reductionA study in Uganda demonstrated a 47 percent reduction in mother to child transmission following the administration of a single dose of nevirapine to the mother at onset of labor and to the baby within 72 hours after birth. The combination of AZT and lamivudine in a short-course regimen also has been shown to reduce mother to child transmission. Anti-Retroviral Based Prevention Strategies

21. 21 Protecting Health Care Workers During Labor and Delivery Precautions during labor: –Protection from blood and amniotic fluids –Protection from sharp instruments Resuscitation of baby: –No mouth to mouth suction –No mouth to mouth breathing Precautions following labor: –Proper disinfection of instruments –Proper disposal of placenta and other items

22. PRETEST COUNSELING TAKE RISK HISTORY AND COUNCIL REGARDING RISK REDUCTION DISCUSS REASONS FOR TEST PROVIDE INFORMATION TO WOMEN REGARDING TESTING & ILLNESS RISKS & BENEFITS OF TESTING CONFIDENTIALITY OF RESULTS ASSESS WINDOW PERIOD PERSON HAS RIGHT TO REFUSE TESTING

23. POST-TEST COUNSELING HIV RESULTS SHOULD BE GIVEN IN PERSON ASSESS PATIENT’S UNDERSTANDING ENCOURAGE PATIENT TO EXPRESS FEELINGS AND ASK QUESTIONS NEGATIVE AND INDETERMINATE RESULTS: DISCUSS NEED FOR REPEAT TESTING

24. POSITIVE RESULT IDENTIFY IMMEDIATE CONCERNS IDENTIFY SUPPORTS EFFECT OF HIV ON PREGNANCY RISK OF TRANSMISSION TO FETUS DURING PREGNANCY, L&D, BF MEASURES TO DECREASE HIV TRANSMISSION

26. ANTENATAL CARE

27. INTRODUCTION MULTIDISCIPLINARY TEAM APPROACH MEDICAL NEEDS SOCIAL AND PSYCHOLOGICAL NEEDS

28. ANTENATAL CARE SIMILAR TO CARE FOR HIV NEGATIVE WOMEN PREGNANCY NOT HIGH RISK SAME NUMBER OF ANTENATAL VISITS AVOID INVASIVE ANTENATAL TESTS OR PROCEDURES

29. FIRST VISIT PATIENT HISTORY DATES OF 1ST POSITIVE HIV TEST HIV RISK FACTORS HIV CARE AT TIME OF CONCEPTION SEROLOGIC STATUS OF PARTNER OTHER STD’S OPPORTUNISTIC INFECTIONS DRUG HISTORY

30. FIRST VISIT INVESTIGATIONS CBC & DIFFERENTIAL LYTES, GLUCOSE, RFT’S, LFT’S, LIVER ENZYMES CD4+ COUNT, CD8 COUNT, CD4/CD8 VIRAL LOAD SEROLOGY FOR HEP A, B, C, SYPHILIS, RUBELLA, TOXO, CMV TB SKIN TEST

31. FOLLOW UP VISITS STANDARD OBSTETRICAL ROUTINE INCREASE SURVEILLANCE ONLY IF WARRANTED LABS EVERY 3 MONTHS CD4+ COUNT VIRAL LOAD SEROLOGY FOR TOXOPLASMOSIS AND SYPHILIS

32. OPPORTUNISTIC INFECTIONS PROPHYLAXIS SHOULD BE OFFERED IN PREGNANCY FOR THE FOLLOWING PNEUMOCYSTIS CARINII PNEUMONIA TOXOPLASMOSIS TUBERCULOSIS MYCOBACTERIUM AVIUM COMPLEX VARICELLA ZOSTER HEPATITIS A, B

33. CONCLUSION HIV IN PREGNANCY SHOULD BE MANAGED BY MULTIDISCIPLINARY TEAM ANTENATAL CARE IS SIMILAR TO THAT OF HIV POSITIVE WOMEN PREGNANCY NOT CONSIDERED HIGH RISK SIMPLY BY VIRTUE OF HIV INFECTION

34. ANTIRETROVIRAL USE

35. ANTEPARTUM ANTIRETROVIRAL USE GOALS: –CONTROL DISEASE IN MOTHER –REDUCE PERINATAL TRANSMISSION VERY LITTLE DATA AVAILABLE ON EFFECTS IN PREGNANCY MOST DATA ASSESSES ZIDOVUDINE LITTLE DATA ON OTHER DRUGS

36. CONCLUSIONS ZIDOVUDINE REDUCES PERINATAL TRANSMISSION IN WOMEN AT DIFFERENT STAGES OF DISEASE LONG AS WELL AS SHORTER REGIMENS EFFECTIVE STILL EFFECTIVE IN BREASTFEEDING POPULATIONS USE OF OTHER ANTIRETROVIRALS IN COMBINATION WITH ZDV PROMISING, STILL INVESTIGATIONAL

37. IN UTERO EXPOSURE

38. CSkeletalAbacavir CHydrocephalu s Zalcitabine BNot carcinogenic Not teratogenic Didanosine CLiver and urinary tumours Not teratogenic Stavudine CNot teratogenic Lamivudine FDA Pregnancy Category Carcinogenicity in animals Teratogenicity In animals (rodents) Drug NRTI’s

39. IN UTERO EXPOSURE BNot teratogenicNelfinavir CIncreased hyperbilirubinemia in monkeys - neonatal Incr. supranumery & cervical ribs Indinavir BNot teratogenicSaquinav ir BSlight incr. in cryptorchidism Ritonavir FDA Pregnancy Category Non Teratogenic Effects Teratogenicity in Animals Drug PI’s

40. ANTIRETROVIRAL THERAPY DURING LABOR & DELIVERY

41. IV ZIDOVUDINE ZDV LOADING DOSE AT ONSET OF LABOR 2MG/KG OVER 1 HR CONTINUOUS INFUSION WHILE IN LABOR 1MG/KG/HR

42. INCREASING EVIDENCE THAT MOST PERINATAL TRANSMISSION OCCURS NEAR TIME OF OR DURING DELIVERY REDUCTION OF PERINATAL TRANSMISSION DUE TO SYSTEMIC ANTIRETROVIRAL DRUG LEVELS IN NEONATE AT TIME OF DELIVERY

43. IV ZIDOVUDINE ZDV READILY CROSSES PLACENTA INITIAL IV DOSE RESULTS IN VIRUCIDAL LEVELS IN MOM & INFANT CONTINUOUS INFUSION ENSURES STABLE DRUG LEVELS IN INFANT DURING BIRTH

44. ORAL ZIDOVUDINE IF IV ZDV NOT AVAILABLE, ORAL ZDV MAY BE USED INTRAPARTUM ZDV 600MG PO @ ONSET OF LABOR 300MG PO Q3H IN LABOR

45. BANGKOK, LANCET 1999 RANDOMIZED PLACEBO CONTROLLED ZDV 300MG PO BID FROM 36WKS GA UNTIL ONSET OF LABOR 300MG PO Q3H WHILE IN LABOR ALL WOMEN ADVISED NOT TO BREASTFEED TRANSMISSION RATES: 9.4% IN RX GROUP; 18.9% IN CONTROL GROUP

46. ABIDJAN, LANCET 1999 SIMILAR TRIAL TO BANGKOK, BUT IN BREASTFEEDING WOMEN

47. COTE D’IVOIRE & BURKINA FASO, LANCET 1999 PLACEBO VS ZDV STARTED @ 36-38 WKS GA 300MG PO DAILY 600MG PO AT ONSET OF LABOR 300MG PO BID UNTIL 7 DAYS PP >85% OF INFANTS BREASTFED >3MOS 18% VS 27.5 % TRANSMISSION @ 6MOS (38% EFFICACY)

48. RESULTS SHOW SHORT-COURSE PO ZDV SAFE & EFFECTIVE IN  ING RISK OF MOTHER-TO-CHILD TRANSMISSION PREVENTION RATES NOT AS HIGH AS WITH IV ZDV

49. ORAL NEVIRAPINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VERY LONG HALF-LIFE RAPID DEV’T OF DRUG RESISTANCE

50. HIVNET 012 STUDY GUAY ET AL - 1999 13626  RANDOMIZED - NVP VS ZDV NVP REGIMEN 200MG PO AT ONSET OF LABOR 2MG/KG PO DOSE TO BABY  72HR DEL’Y ZDV REGIMEN 600MG PO AT ONSET OF LABOR 300MG PO Q3H DURING LABOR 4MG/KG BID x7 DAYS TO INFANTS

51. HIVNET 012 - RESULTS

52. SO WHAT? EFFICACY OF SHORT-COURSE NVP 47% GREATER THAN SHORT COURSE ZDV CURRENTLY SHORT-COURSE PO NVP NOT COMPARED TO IV ZDV FOR TRANSMISSION PREVENTION

53. CONCLUSIONS DURING LABOR - ZDV 2MG/KG IV LOADING DOSE, THEN 1MG/KG/HR IF IV ZDV NOT AVAILABLE CONSIDER PO REGIMEN MAY CONSIDER ADDITION OF NVP 200MG PO TO IV ZDV @ ONSET OF LABOR

54. OBSTETRICAL PRACTICE

55. 70 % OF HIV TRANSMISSION OCCURS INTRAPARTUM. THE GOAL OF OBSTETRICAL MANAGEMENT OF THE HIV PATIENT IS TO AVOID THOSE PRACTICES THAT INCREASE RISK OF TRANSMISSION.

56. OBSTETRICAL PRACTICE RUPTURE OF MEMBRANES LANDESMAN ET AL., 1996 RUPTURED MEMBRANES ONE OF MANY VARIABLES EXAMINED 281 MOTHER-CHILD PAIRS WITH MEMBRANES RUPTURED LESS THAN 4 HOURS 206 MOTHER-CHILD PAIRS WITH MEMBRANES RUPTURED MORE THAN 4 HOURS

57. RUPTURE OF MEMBRANES LANDESMAN ET AL., 1996

58. OBSTETRICAL PRACTICE MODE OF DELIVERY - VAGINAL ARTIFICIAL RUPTURE OF MEMBRANES SHOULD BE AVOIDED RUPTURE OF MEMBRANES PAST 4 HOURS SHOULD BE AVOIDED FETAL SCALP SAMPLING AND THE USE OF SCALP ELECTRODES SHOULD BE AVOIDED

59. MODE OF DELIVERY: EUROPEAN MODE OF DELIVERY COLLABORATION – MARCH, 1999 RANDOMIZED CLINICAL TRIAL 370 MOTHER-CHILD PAIRS ANALYZED 203 DELIVERED BY C-S 167 DELIVERED VAGINALLY

60. MODE OF DELIVERY: EUROPEAN MODE OF DELIVERY COLLABORATION – MARCH, 1999

61. 203 C-S PERFORMED 165 WERE PERFORMED ELECTIVELY 31 WERE PERFORMED EMERGENTLY

62. MODE OF DELIVERY: EUROPEAN MODE OF DELIVERY COLLABORATION – MARCH, 1999

63. MODE OF DELIVERY: META-ANALYSIS THE INTERNATIONAL PERINATAL HIV GROUP, APRIL 1999 15 PROSPECTIVE COHORT STUDIES 8533 MOTHER-CHILD PAIRS REDUCTION OF TRANSMISSION 50% (OR 0.43, 95% CI, 0.33 – 0.56) WITH ELECTIVE C-S VS. OTHER MODES OF DELIVERY REDUCTION OF TRANSMISSION 87% (OR 0.13, 95% CI, 0.09 – 0.19) WITH ELECTIVE C-S & PACTG 076

64. MODE OF DELIVERY – CAESAREAN SECTION HIV INFECTED WOMEN SHOULD BE COUNSELLED ABOUT ELECTIVE C-S VERTICAL TRANSMISSION IS REDUCED TO 2% WITH PACTG 076 THERAPY AND ELECTIVE C-S WOMEN WITH HIGH VIRAL LOADS MAY BENEFIT MOST FROM C-S TO AVOID SROM & ONSET OF LABOUR, ELECTIVE C-S IS PERFORMED AT 38 WEEKS AFTER SROM OR ONSET OF LABOUR C-S IS LESS PROTECTIVE TO AVOID C-S MORBIDITY, ANTIBIOTIC PROPHYLAXIS SHOULD BE CONSIDERED

65. VIRAL LOAD

66. HIV IN PREGNANCY – VIRAL LOAD WOMEN AND INFANTS TRANSMISSION STUDY (WITS): GARCIA ET AL., 1999 26 of 64Greater than 100,000 17 of 5450,001 – 100,000 39 of 18310,001 – 50,000 32 of 1931,000 – 10,000 0 of 57Less than 1,000 Number of HIV Transmissions HIV Viral Load (Copies per mL)

67. HIV IN PREGNANCY – VIRAL LOAD WOMEN AND INFANTS TRANSMISSION STUDY (WITS): GARCIA ET AL., 1999

68. BREASTFEEDING IN HIV POSITIVE WOMEN

69. INTRODUCTION HIV DNA PRESENT IN BREAST MILK HIV TRANSMISSION CAN OCCUR THROUGH BREASTFEEDING BREASTFEEDING IS AN INDEPENDENT RISK FACTOR FOR HIV TRANSMISSION

70. EVIDENCE TO SUPPORT TRANSMISSION ISOLATION OF HIV-1 FROM CELLULAR & NON-CELLULAR FRACTIONS OF BREAST MILK CASE REPORTS OF INFECTED CHILDREN BREASTFED BY MOTHERS WHO ACQUIRED HIV POSTPARTUM

71. EVIDENCE TO SUPPORT TRANSMISSION DOCUMENTATION OF OTHER RETROVIRUSES TRANSMITTED THROUGH BREAST MILK CASE REPORTS OF BREAST FED CHILDREN WHO WERE INITIALLY HIV NEGATIVE BUT SEROCONVERTED DURING BREASTFEEDING

72. POLICIES AVOIDANCE OF BREASTFEEDING IS CONTROVERSIAL AND DEPENDS ON INTERNAL MILIEU DEVELOPING COUNTRIES VS INDUSTRIALIZED COUNTRIES

73. POLICIES UNAIDS REVISED STATEMENT 1998: WOMEN SHOULD BE OFFERED HIV COUNSELING AND TESTING, BE INFORMED OF RISKS AND BENEFITS OF BREASTFEEDING IF THE MOTHER IS HIV POSITIVE, AND SHOULD MAKE A DECISION THAT TAKES INTO ACCOUNT THE INDIVIDUAL &FAMILY SITUATIONS

74. MECHANISM OF TRANSMISSION EXACT MECHANISM OF TRANSMISSION THROUGH BREAST MILK STILL NOT WELL UNDERSTOOD INFECTION VIA CELL-FREE HIV IN BREAST MILK OR VIA HIV-INFECTED CELLS SUSCEPTIBILITY OF IMMATURE NEONATAL GI TRACT TO VIRUS GI TRACT MUCOSAL DAMAGE

75. DURATION OF BREASTFEEDING STUDIES -  IN TRANSMISSION WITH INCREASING DURATION OF BREASTFEEDING

76. MALAWI, JAMA 1999 CUMULATIVE INFECTION RISK WHILE BREASTFEEDING 3.5% AT END OF 5 MONTHS 7.0% AT END OF 11 MONTHS 8.9% AT END OF 17 MONTHS 10.3% AT END OF 23 MONTHS NO FURTHER TRANSMISSION AFTER BREASTFEEDING STOPPED

77. MULTICENTER STUDY, LANCET 1998 CUMULATIVE INFECTION RISK WHILE BREASTFEEDING 0.7% AT END OF 6 MONTHS 0.95% AT END OF 9 MONTHS 2.5% AT END OF 12 MONTHS 6.3% AT END OF 18 MONTHS 7.4% AT END OF 24 MONTHS 9.2% AT END OF 36 MONTHS

78. DURATION OF BREASTFEEDING ? EARLY WEANING POLICY PROBLEMS WITH EARLY WEANING ADVERSE NEONATAL EFFECTS COLOSTRUM HIGHLY INFECTIOUS

79. EXCLUSIVITY OF BRESTFEEDING STUDIES - INFANTS EXCLUSIVELY BREAST FED AT LOWER RISK OF ACQUIRING HIV THAN THOSE FED WITH OTHER TYPES OF MILK, TEA, OR JUICE WHILE BEING BREAST FED

80. BRAZIL STUDY, 1998 CHILDREN FED WITH OTHER TYPES OF MILK WHILE BEING BREASTFED WERE AT 2.2-FOLD GREATER RISK OF HIV INFECTION THAN THOSE EXCLUSIVELY BREASTFED CHILDREN FED WITH TEA OR FRUIT JUICE WHLE BEING BREASTFED WERE AT 2.6-FOLD GREATER RISK OF INFECTION

81. DURBAN (SOUTH AFRICA), LANCET 1999 3 GROUPS OF CHILDREN - NEVER BREASTFED, EXCLUSIVELY BREASTFED, MIXED FEEDING NO SIGNIFICANT DIFFERENCE IN TRANSMISSION BETWEEN NEVER AND EXCLUSIVELY BREASTFED GROUPS SIGNIFICANTLY INCREASED RISK OF TRANSMISSION FOR MIXED FEEDING

82. INTERPRETATION IMMUNE FACTORS IN BREAST MILK GROWTH FACTORS IN BREAST MILK MUCOSAL DAMAGE WITH MIXED FEEDING

83. MATERNAL FACTORS CRACKED NIPPLES BLEEDING NIPPLES PARITY

84. CONCLUSION PRECISE RISK FACTORS AND MECHANISM OF TRANSMISSION STILL NOT WELL UNDERSTOOD WOMEN WHO ARE HIV POSITIVE SHOULD BE ADVISED TO AVOID BREASTFEEDING WOMEN WHO BREASTFEED SHOULD BE INFORMED THAT TRANSMISSION CAN OCCUR

85. SUMMARY

86. HIV SCREENING ALL PREGNANT WOMEN SHOULD BE OFFERRED HIV TESTING PRE- & POST- TEST COUNSELING FOR ALL PREGNANT WOMEN TARGETED TESTING OF PREGNANT WOMEN WHO REPORT HIGH RISK BEHAVIOR NOT RECOMMENDED

87. ANTENATAL CARE HIV IN PREGNANCY REQUIRES MULTIDISCIPLINARY APPROACH ANTENATAL CARE IS SIMILAR TO THAT OF HIV -VE WOMEN PREGNANCY NOT HIGH RISK AVOID INVASIVE PROCEDURES MONITOR CD4+ AND VIRAL LOAD AT LEAST EVERY 3 MONTHS IF ABLE TO PROVIDE ANTIRETROVIRAL THERAPY

88. ANTIRETROVIRAL USE Zidovudine reduces perinatal transmission in women at different stages of disease long (ante, peri, and postnatal) as well as shorter regimens effective still effective in breastfeeding populations Use of other antiretrovirals in combination with ZDV promising, still investigational

89. INTRAPARTUM ANTIRETROVIRAL THERAPY DURING LABOR - ZDV 2MG/KG IV LOADING DOSE, THEN 1MG/KG/HR IF IV ZDV NOT AVAILABLE CONSIDER PO REGIMEN MAY CONSIDER ADDITION OF NVP 200MG PO TO IV ZDV @ ONSET OF LABOR

90. BREASTFEEDING PRECISE RISK FACTORS AND MECHANISM OF TRANSMISSION STILL NOT WELL UNDERSTOOD WOMEN WHO ARE HIV POSITIVE SHOULD BE ADVISED TO AVOID BREASTFEEDING WOMEN WHO BREASTFEED SHOULD BE INFORMED THAT TRANSMISSION CAN OCCUR